The protocol specifies a primary outcome of histological improvement, defined as MASH resolution or fibrosis reduction. Secondary outcomes include changes in liver enzymes, metabolic parameters, and adverse events. The planned review does not report a sample size, follow-up duration, setting, or funding sources.
No results are presented. The protocol contains no pooled effect estimates, no safety data, and no conclusions about the efficacy or tolerability of GLP-1 receptor agonists in this population. Limitations of the eventual review are not described in the protocol.
Because this is a protocol, it cannot inform clinical decisions at this stage. It signals that a systematic synthesis on this question is planned, but clinicians should await the completed review before drawing any conclusions about the role of GLP-1 receptor agonists in MASH.
How this fits prior evidence
This protocol addresses a gap in prior coverage, which has not yet synthesized GLP-1 receptor agonist outcomes for MASH. Prior coverage includes a phase 2 trial in which semaglutide monotherapy showed significant improvement in liver fibrosis, while zalfermin combinations did not reach significance. Other covered findings concern SGLT2 inhibitors in diabetic retinopathy and bladder cancer risk, thiazolidinedione bladder cancer risk, a genetic risk variant for MASLD, and AI applications in MASLD diagnosis. The planned review may clarify the histological and metabolic effects of GLP-1 receptor agonists, but no results are yet available.
Living with metabolic dysfunction-associated steatohepatitis (MASH) means dealing with a liver that is struggling with both fat buildup and inflammation. Doctors are looking for better ways to treat this condition, and one promising path involves a specific class of medications called GLP-1 receptor agonists.
Researchers have designed a new plan to gather and analyze data on these drugs. They want to see if these medications can actually improve the physical structure of the liver, specifically by reducing scarring and resolving the underlying inflammation. They will also track changes in liver enzymes and general metabolic health.
Because this is a plan for a future review, there are no results to share just yet. The study will eventually help doctors understand if these drugs are a reliable option for patients. Since the data is not yet available, we cannot know the safety profile or the effectiveness of the treatment at this time.
What this means for you:
A new research plan will soon test if GLP-1 drugs can improve liver health in patients with MASH.
Common questions
What is MASH and how is it treated?
MASH is a condition where the liver has both fat buildup and inflammation. This study plans to look at whether GLP-1 receptor agonists can help improve liver health and reduce scarring for adults with this condition.
Are GLP-1 drugs safe for liver disease?
Because this is a plan for a future review, no safety data or results are available yet. The study will eventually track side effects and how well the drugs are tolerated by patients.
More on Metabolic Dysfunction-Associated Steatohepatitis
BackgroundMetabolic dysfunction-associated steatohepatitis (MASH) is a major global chronic liver disease without approved pharmacotherapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show therapeutic promise due to their multi-faceted metabolic benefits, but their efficacy on histological endpoints in MASH requires definitive synthesis.Methods and analysisWe will conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating GLP-1 RAs versus placebo/standard care in adults with MASH. Literature searches will be performed in PubMed, Embase, Cochrane Library, and Web of Science. Two reviewers will independently screen studies, extract data, and assess risk of bias using Cochrane's ROB 2 tool. The primary outcome is histological improvement (MASH resolution/fibrosis reduction). Secondary outcomes include changes in liver enzymes, metabolic parameters, and adverse events. Data will be pooled using random-effects models. Trial Sequential Analysis (TSA) will be performed to control random errors and evaluate evidence robustness. Subgroup and sensitivity analyses are planned.Ethics and disseminationEthical approval is not required because this study is a secondary analysis of existing data. We will disseminate the findings through peer- reviewed publications.Systematic Review RegistrationPROSPERO CRD420261287573.
